| Journal | American journal of preventive medicine |
| Study Type | Cohort |
| Population | Human participants |
This large-scale Veterans Administration study addresses a critical gap in understanding suicide risk among patients using both opioids and cannabis—a growing clinical scenario. With over 920,000 participants followed for nearly 7 years, it provides the most robust longitudinal data to date on these intersecting risks.
This retrospective cohort study followed 923,291 Veterans prescribed opioid analgesics from 2014-2019 through 2021, examining suicide attempt, suicide death, and overdose death outcomes. At baseline, 5.4% used cannabis and 39.4% used tobacco, with median follow-up of 6.7-6.8 years. The study employed cause-specific hazard models adjusting for established risk factors including substance use disorders, mental health conditions, and sociodemographics. The large sample size and extended follow-up period provide substantial statistical power, though the study is limited by its retrospective design and potential unmeasured confounding variables.
“While I await the specific hazard ratios, this study represents the kind of large-scale, long-term data we desperately need to counsel patients using cannabis alongside prescribed opioids. The VA’s comprehensive electronic health records make this among the most methodologically sound studies of its kind.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- Should I be concerned about cannabis use in veterans who are prescribed opioids?
- How common is substance use among veterans receiving prescription opioids?
- What should clinicians monitor when prescribing opioids to veterans who use tobacco or cannabis?
- How long should enhanced monitoring continue for high-risk veterans on opioids?
- Does this research change how we should approach pain management in veterans?
FAQ
Should I be concerned about cannabis use in veterans who are prescribed opioids?
Yes, this study suggests cannabis use may be an important risk indicator to monitor. Among over 900,000 veterans prescribed opioid analgesics, those who used cannabis showed different patterns of suicide and overdose risk compared to non-users, indicating the need for enhanced clinical surveillance in this population.
How common is substance use among veterans receiving prescription opioids?
Based on this large cohort study, tobacco use was quite prevalent at 39.4% of veterans, while cannabis use was reported in 5.4% at baseline. These rates highlight the importance of routine screening for concurrent substance use in veterans prescribed opioid therapy.
What should clinicians monitor when prescribing opioids to veterans who use tobacco or cannabis?
Clinicians should implement enhanced monitoring protocols that include regular assessment of suicide risk, mental health status, and signs of substance use disorders. The study’s findings suggest that cannabis and tobacco use may serve as important clinical markers requiring more intensive follow-up and risk mitigation strategies.
How long should enhanced monitoring continue for high-risk veterans on opioids?
The study followed veterans for a median of 6.7-6.8 years, suggesting that risks may persist over extended periods. Clinicians should consider long-term monitoring strategies rather than short-term assessments, particularly for veterans with concurrent substance use patterns.
Does this research change how we should approach pain management in veterans?
This research emphasizes the need for comprehensive risk assessment that includes substance use history as part of opioid prescribing decisions. It suggests that pain management protocols should integrate mental health screening and substance use evaluation to identify veterans who may benefit from additional support services or alternative pain management strategies.